<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00559494</url>
  </required_header>
  <id_info>
    <org_study_id>17007</org_study_id>
    <secondary_id>PVA2414</secondary_id>
    <nct_id>NCT00559494</nct_id>
  </id_info>
  <brief_title>Minocycline and Perfusion Pressure Augmentation in Acute Spinal Cord Injury</brief_title>
  <official_title>A Pilot Study to Assess Clinical Safety and Tolerance of Minocycline and Spinal Perfusion Pressure Augmentation in Acute Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Paralyzed Veterans of America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Association of Neurological Surgeons</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hotchkiss Brain Institute, University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While research in animal models of spinal cord injury have provided many promising insights,&#xD;
      human studies have failed to produce effective therapies. We propose to investigate the drug&#xD;
      Minocycline (a metalloproteinase inhibitor) for the treatment of spinal cord injured patients&#xD;
      aiming to limit neurological injury and improve neurological outcome. This drug influences&#xD;
      several secondary injury mechanisms implicated in spinal cord injury and has been effective&#xD;
      in improving outcome after spinal cord injury in animal models. We also propose to examine&#xD;
      the safety and feasibility of spinal cord perfusion pressure augmentation with a protocol of&#xD;
      IV fluids and inotrope medications versus standard maintenance of mean arterial pressure in&#xD;
      subjects who exhibit a decrease in perfusion pressure to less than 75 mmHg. The purpose of&#xD;
      this pilot study is 1) to evaluate the feasibility of a clinical trial protocol for&#xD;
      Minocycline in patients with acute spinal cord injury, and 2) to ensure adequate drug dosing&#xD;
      and metabolic effect. After undergoing a process of informed consent, patients agreeing to&#xD;
      participate in the study will be randomized to placebo or treatment groups in a double-blind&#xD;
      fashion. Clinical neurological examinations, patient-reported quality of life, and functional&#xD;
      independence categorization will be combined with serum and cerebrospinal fluid laboratory&#xD;
      investigations to establish some of the pharmacological properties and the safety profile of&#xD;
      this medication in this group of patients. In addition, patient tolerance to the dosing&#xD;
      regimen will be assessed. The results of this study will provide the preliminary data&#xD;
      necessary to plan for a larger prospective, randomized, controlled, double-blind clinical&#xD;
      trial to assess efficacy and to further assess safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Protocol compliance, feasibility and adverse events</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>American Spinal Injury Association - motor score (primary clinical outcome) and sensory scores</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36 - Quality of Life Assessment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Independence Measure</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>London Handicap Scale</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spinal Cord Injury Measure</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF collection (6/day) and biochemical assays</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Anatomical MRI</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SCPP augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SCPP control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>Minocycline IV BID x 7 days (first 10 patients 200 mg/dose, subsequent patients adjusted based on pharmacodynamic profiling to 800 mg loading dose, tapered 100 mg each dose to 400 mg then maintain at 400mg until day 7)</description>
    <arm_group_label>Minocycline</arm_group_label>
    <other_name>Minocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Normal saline 250cc via central line similar to minocycline arm administration protocol</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>control</other_name>
    <other_name>saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SCPP augmentation</intervention_name>
    <description>maintenance of spinal cord perfusion pressure at 75 mmHg with fluids and inotrope protocol</description>
    <arm_group_label>SCPP augmentation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SCPP control</intervention_name>
    <description>maintenance of Mean arterial pressure of &gt;65 mmHg with fluids and inotropes protocol without spinal cord perfusion pressure as target or guiding therapy</description>
    <arm_group_label>SCPP control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 16 or over&#xD;
&#xD;
          -  Motor complete or motor incomplete acute spinal cord injury involving bony spinal&#xD;
             levels between C0 and T11&#xD;
&#xD;
          -  Patient able to provide informed consent&#xD;
&#xD;
          -  Randomization and commencement of administration of first drug dose within 12 hours of&#xD;
             injury&#xD;
&#xD;
          -  surgical decompression if needed to be performed within 24 hours of the injury&#xD;
&#xD;
          -  subjects exhibiting spinal cord perfusion pressure (lumbar drain transduced pressure -&#xD;
             mean arterial pressure)&gt; 75 mmHg will be randomized to active augmentation protocol&#xD;
             versus maintenance of mean arterial pressure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute spinal cord injury &gt;12 hours old&#xD;
&#xD;
          -  Isolated sensory deficit, motor intact&#xD;
&#xD;
          -  Isolated cauda equina injury or injury at bony level T12 or below&#xD;
&#xD;
          -  History of systemic lupus erythematosus (SLE)&#xD;
&#xD;
          -  Pre-existing hepatic or renal disease&#xD;
&#xD;
          -  Tetracycline hypersensitivity&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Isolated sensory deficit&#xD;
&#xD;
          -  Isolated radicular motor deficit&#xD;
&#xD;
          -  Significant leukopenia (white blood cell count &lt; Â½ times the lower limit of normal) at&#xD;
             screening&#xD;
&#xD;
          -  Elevated liver function tests (AST, ALT, alkaline phosphatase, or total bilirubin &gt; 2&#xD;
             times the upper limit of normal) at screening&#xD;
&#xD;
          -  Presence of systemic disease that might interfere with patient safety, compliance or&#xD;
             evaluation of the condition under study (e.g. insulin-dependent diabetes, Lyme&#xD;
             disease, clinically significant cardiac disease, HIV, HTLV-1)&#xD;
&#xD;
          -  Associated traumatic conditions interfering with informed consent or outcome&#xD;
             assessment (e.g. closed head injury, liver contusion)&#xD;
&#xD;
          -  Known uncorrected severe coronary artery disease or evidence of active coronary&#xD;
             ischemia (ECG changes, positive Troponin) will be excluded from SCPP randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Casha, MD PhD FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. John Hurlbert, MD PhD FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Zygun, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Casha S, Zygun D, McGowan MD, Bains I, Yong VW, Hurlbert RJ. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain. 2012 Apr;135(Pt 4):1224-36. doi: 10.1093/brain/aws072.</citation>
    <PMID>22505632</PMID>
  </results_reference>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>November 14, 2007</study_first_submitted>
  <study_first_submitted_qc>November 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2007</study_first_posted>
  <last_update_submitted>March 15, 2013</last_update_submitted>
  <last_update_submitted_qc>March 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Steve Casha</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>complete spinal cord injury</keyword>
  <keyword>incomplete spinal cord injury</keyword>
  <keyword>central cord spinal cord injury</keyword>
  <keyword>traumatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

